<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036061</url>
  </required_header>
  <id_info>
    <org_study_id>108414</org_study_id>
    <nct_id>NCT01036061</nct_id>
  </id_info>
  <brief_title>GSK618334 Repeat Dose Study</brief_title>
  <official_title>A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GSK618334 strongly binds to dopamine type 3 receptors in the human brain and is being
      developed as an innovative treatment for substance dependence. This study will evaluate the
      safety, tolerability, blood concentrations and effect following repeated oral doses of
      GSK618334 in healthy male and female volunteers. The effect of food on a single oral dose of
      GSK618334 will also be evaluated. Another portion of this study will investigate dopamine
      type 3 receptor binding in the human brain by PET scan before and after repeated doses of
      GSK618334.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2009</start_date>
  <completion_date type="Actual">February 17, 2010</completion_date>
  <primary_completion_date type="Actual">February 17, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability endpoints will be: adverse events, laboratory values, cardiovascular variables (blood pressure, heart rate, ECG), temperature, respiratory rate, assessment of mood and abnormal movements, and GSK618334 blood levels.</measure>
    <time_frame>First dose to follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess blood concentrations of GSK618334 after repeated oral doses.</measure>
    <time_frame>First dose to 72 hours post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of food on GSK618334 blood concentrations after a single dose.</measure>
    <time_frame>First dose of the single dose session to 24 hours after dosing of the repeat dose session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dopamine type 3 receptor binding in the brain (by PET scan) of GSK618334 following the repeat dose session.</measure>
    <time_frame>First dose to 24 hours after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Substance Dependence</condition>
  <arm_group>
    <arm_group_label>GSK618334 low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK618334 Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK618334 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK618334 medium dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK618334 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK618334 High Dose Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK618334 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for all 3 dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK618334 Low Dose</intervention_name>
    <description>GSK618334 low dose</description>
    <arm_group_label>GSK618334 Placebo</arm_group_label>
    <arm_group_label>GSK618334 low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK618334 PET subjects</intervention_name>
    <description>PET subjects</description>
    <arm_group_label>GSK618334 High Dose</arm_group_label>
    <arm_group_label>GSK618334 Medium Dose</arm_group_label>
    <arm_group_label>GSK618334 low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK618334 Medium Dose</intervention_name>
    <description>Medium Dose</description>
    <arm_group_label>GSK618334 Medium Dose</arm_group_label>
    <arm_group_label>GSK618334 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK618334 High Dose</intervention_name>
    <description>GSK618334 High Dose</description>
    <arm_group_label>GSK618334 High Dose</arm_group_label>
    <arm_group_label>GSK618334 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Males and Females between the ages of 18-50 years old

          -  Male and Female subjects must agree to use protocol specified contraceptive methods.

          -  Male subjects only in PET parts of the study.

          -  Capable of providing written informed consent.

        Exclusion Criteria:

          -  A positive test for Hepatitis B or Hepatitis C within 3 months of screening.

          -  Current or chronic history of liver disease, or known liver/bile/gallbladder
             abnormalities.

          -  Personal or family history of heart disease (such as irregular heart beats, a history
             of sudden unexplained death in a first degree relative, or unexplained fainting).

          -  Screening ECG parameters outside the protocol specified parameters.

          -  Pulse rate &lt;50 or &gt;100 bpm OR a systolic blood pressure &gt;140 or &lt;95 mmHg OR a
             diastolic blood pressure &gt;90 or &lt;50 mmHg at screening and/or baseline.

          -  Pregnant or lactating females.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Previous inclusion in a research and/or medical protocol involving nuclear medicine,
             PET or radiological investigations with significant radiation burden.

          -  Significant suicidal risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/108414?search=study&amp;search_terms=108414#rs</url>
    <description>Results for study 108414 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>compulsive discorders</keyword>
  <keyword>addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108414</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

